Literature DB >> 16538052

Posttransplant lymphoproliferative disorder after umbilical cord blood transplantation in children.

Jerald Z Gong1, Michael G Bayerl, Linda M Sandhaus, Siby Sebastian, Catherine W Rehder, Mark Routbort, Anand S Lagoo, Paul Szabolcs, Jeanie Chiu, Melanie Comito, Patrick J Buckley.   

Abstract

Reported are 7 cases of posttransplant lymphoproliferative disorder (PTLD) arising in children who received umbilical cord blood transplantation (UCBT). There were 4 females and 3 males with a median age of 3 years (range, 1-16 years). All 7 patients received UCBT, including 1 patient who received multiple units and 1 transplanted under nonmyeloablative condition. The time interval from UCBT to PTLD averaged 4 months (range, 2 weeks to 9 months). Patients typically presented with high-stage disease with visceral organ involvement. Histology of the PTLDs showed monomorphic morphology in 5 cases and polymorphic morphology in the remaining 2 cases. Bone marrow biopsies were performed in 3 cases and were negative for PTLD. Epstein-Barr virus (EBV) was detected in the PTLD in all 7 patients by in situ hybridization. Evidence of past EBV infection was found in the recipients, but the EBV genome was not detected in the donor cord blood samples, suggesting that donor cord blood was not the source of EBV infection. The origin of the PTLD was investigated in 5 cases. PTLD was of host origin in 2 patients who failed engraftment and of donor origin in the remaining 3 patients who had complete engraftment. Four of 5 patients with monomorphic PTLD failed to demonstrate significant responses to rituximab and/or reduction of immunosuppression and died within 1 month after diagnosis. The remaining 2 patients with polymorphic PTLD showed complete response to therapy. One patient was alive 35 months after transplant, and the other patient died of infection 6 months after transplant. It is concluded that PTLD arising after UCBT in children occurs early after transplant and represents a serious EBV-related complication. PTLD may be of donor or recipient origin depending on engraftment status. Both monomorphic and polymorphic histology may be seen, and monomorphic histology appears to predict an unfavorable prognosis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16538052     DOI: 10.1097/01.pas.0000188030.63706.e7

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  4 in total

Review 1.  Treatment with rituximab in benign and malignant hematologic disorders in children.

Authors:  Lisa B Giulino; James B Bussel; Ellis J Neufeld
Journal:  J Pediatr       Date:  2007-04       Impact factor: 4.406

Review 2.  Donor cell leukemia in umbilical cord blood transplant patients: a case study and literature review highlighting the importance of molecular engraftment analysis.

Authors:  Jennifer Crow; Kenneth Youens; Susan Michalowski; Gail Perrine; Cassandra Emhart; Felicia Johnson; Amy Gerling; Joanne Kurtzberg; Barbara K Goodman; Siby Sebastian; Catherine W Rehder; Michael B Datto
Journal:  J Mol Diagn       Date:  2010-04-29       Impact factor: 5.568

Review 3.  EBV-induced post transplant lymphoproliferative disorders: a persisting challenge in allogeneic hematopoetic SCT.

Authors:  L Rasche; M Kapp; H Einsele; S Mielke
Journal:  Bone Marrow Transplant       Date:  2013-07-08       Impact factor: 5.483

Review 4.  Diagnosis and treatment of viral diseases in recipients of allogeneic hematopoietic stem cell transplantation.

Authors:  Ren Lin; Qifa Liu
Journal:  J Hematol Oncol       Date:  2013-12-17       Impact factor: 17.388

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.